Overview

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2020-03-03

Target enrollment:

Participant gender:

Summary

To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

ARMO BioSciences

Treatments:

Nivolumab